Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 10,325 | 2,816 | 21,049 | 13,535 | 10,141 |
| Gross Profit | 10,325 | 2,816 | 21,049 | 13,535 | 10,141 |
| Operating Expenses | 146,138 | 137,637 | 114,507 | 80,171 | 58,782 |
| Operating Income | -135,813 | -134,821 | -93,458 | -66,636 | -48,641 |
| Interest Expense | 2,769 | 3,653 | 3,759 | 1,176 | 0 |
| Other Income | 8,816 | 10,975 | 7,999 | 1,591 | 16 |
| Pre-tax Income | -129,766 | -127,499 | -89,218 | -66,221 | -48,625 |
| Net Income Continuous | -129,766 | -127,499 | -89,218 | -66,221 | -48,625 |
| Net Income | $-129,766 | $-127,499 | $-89,218 | $-66,221 | $-48,625 |
| EPS Basic Total Ops | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 |
| EPS Basic Continuous Ops | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 |
| EPS Diluted Total Ops | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 |
| EPS Diluted Continuous Ops | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 |
| EPS Diluted Before Non-Recurring Items | -1.00 | -1.13 | -1.36 | -2.75 | -4.17 |
| EBITDA(a) | $-132,947 | $-130,713 | $-88,097 | $-61,499 | $-45,313 |